Newswire (Published: Tuesday, November 12, 2019, Received: Tuesday, November 12, 2019, 3:50:29 PM CST)
Word Count: 451
2019 NOV 12 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news originating from Seattle, Washington, by NewsRx correspondents, research stated, “Prostate cancer is ubiquitous in older men; differential screening patterns and variations in biopsy recommendations and acceptance will affect which man is diagnosed and, therefore, evaluation of cancer risk factors. We describe a statistical method to reduce prostate cancer detection bias among African American (n=3398) and Non-Hispanic White men (n=22,673) who participated in the Selenium and Vitamin E Cancer Prevention trial (SELECT) and revisit a previously reported association between race, obesity and prostate cancer risk.”
Financial support for this research came from National Cancer Institute of the USA.
Our news journalists obtained a quote from the research from Fred Hutchinson Cancer Research Center, “For men with screening values suggesting prostate cancer but in whom biopsy was not performed, the Prostate Cancer Prevention Trial Risk Calculator was used to estimate probability of prostate cancer. Associations of body mass index (BMI) and race with incident prostate cancer were compared for observed versus imputation-enhanced outcomes using incident density ratios. Accounting for differential biopsy assessment, the previously reported positive linear trend between BMI and prostate cancer in African American men was not observed; no BMI association was found among Non-Hispanic White men. Differential disease classification among men who may be recommended to undergo and then consider whether to accept a prostate biopsy leads to inaccurate identification of prostate cancer risk factors. Imputing a man’s prostate cancer status reduces detection bias. Covariate adjustment does not address the problem of outcome misclassification.”
According to the news editors, the research concluded: “Cohorts evaluating incident prostate cancer should collect longitudinal screening and biopsy data to adjust for this potential bias.”
For more information on this research see: Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI. Cancer Epidemiology, 2019;63():101619. (Elsevier - www.elsevier.com; Cancer Epidemiology - http://www.journals.elsevier.com/cancer-epidemiology/)
The news correspondents report that additional information may be obtained from C.M. Tangen, From the SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. Additional authors for this research include J. Schenk, C. Till, P.J. Goodman, W. Barrington, M.S. Lucia and I.M Thompson.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.canep.2019.101619. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Fred Hutchinson Cancer Research Center
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues